Resilient’s Incident Response Platform will enable Teva to respond faster and more comprehensively to any cyber security incidents
Resilient Systems (formerly Co3 Systems), the leading Incident Response Platform (IRP) provider, has announced that Teva Pharmaceutical Industries Ltd., a global pharmaceutical company, has selected the Resilient Systems IRP to manage response to cybersecurity incidents.
Following a detailed scope of requirements and analysis of multiple vendors, Teva selected Resilient Systems as the Incident Response partner that best reflected its objectives. The Resilient Systems platform is based on industry best practice from organisations such as the National Institute of Standards and Technology (NIST) and The SANS Institute, which were important in meeting Teva’s requirements. Teva will integrate the platform with many of its key systems, leveraging the Resilient Systems Action Module to increase automation and achieve an integrated Incident Response process.
The frequency and scale of cyber incidents demonstrates that cybercrime is an increasing operational risk for businesses. In the majority of incidents, prevention and detection technologies are already in place, but have been ineffective or incorrectly configured. As a result, organisations affected by security incidents are judged on their subsequent handling and public response. It has become critical for organisations to respond quickly and in detail to incidents – providing an explanation as to what has happened, how it has happened and what is being done to rectify the situation. A failure to do so has an extremely negative impact on public perception and brand value.
Resilient Systems fills this market requirement by providing organisations with a platform from which to achieve an efficient, effective and consistent response to security incidents.
“We’ve witnessed how data breach incidents result in the kind of reputational impact and public scrutiny that inflicts deep and lasting damage on businesses,” said Paul Ayers, General Manager EMEA of Resilient Systems. “Response is clearly a major operational challenge and our platform is designed to replace disparate tools, systems and strategies with an over-arching platform to make it simpler for organisations to decisively act in the event of a security incident.”
The Resilient Systems platform automates the creation of response plans with adjustable dashboards and reports that are accessible by executives, board members and regulators. It is designed to make it much easier to centrally assign incident response tasks, collaborate on their completion, and assess progress. With the appropriate modules in place, businesses can immediately create response plans in regards to individual compliance regulations.
“Teva takes the security of its data and systems extremely seriously,” said Noam Ravid, Head of the Cyber Defense Center at Teva. “We recognise that, alongside prevention and detection technologies, there is a significant need for tools that make it possible to conduct far more coordinated, rapid and detailed responses when security incidents happen to occur.”
About Resilient Systems
Resilient Systems (formerly Co3 Systems) is the leading Incident Response Platform (IRP) provider, empowering organisations to thrive in the face of cyberattacks and business crises. Our collaborative platform arms Incident Response teams with workflows, intelligence, and deep-data analytics to react faster, coordinate better, and respond smarter. Headquartered in Massachusetts, USA, Resilient Systems’ customers are some of the world’s most trusted organisations.
About Teva
Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva’s net revenues in 2014 amounted to $20.3 billion.
